GMV will develop Big Data platform to improve the treatment of blood diseases

The 40-million-euro, 5-year Harmony project has now kicked off as part of the European IMI2 initiative. This project will help doctors’ decision-making processes in their diagnosis and treatment of blood diseases such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Myelodysplastic syndromes (MDS) and blood disorders in babies and children. It will also come up with answers for researchers looking into new, more efficient drugs for more personalized treatment.

GMV is the only private technology firm participating in the project, together with another 50 partners from 11 European countries, including hospitals, research centers, universities, patient organizations and pharmaceutical companies.

GMV’s input to the project is the design and development of the Big Data platform for mass processing of information from anonymous patients provided by the consortium members. On the strength of Big Data technology, GMV will deal with this huge volume of clinical, genetic and molecular data, process it, harmonize it and extract valuable information for answering questions posed by scientists and specialist users of the platform.

Harmony is one of Europe’s biggest public-private initiatives seeking more efficient treatment for blood diseases on the basis of clinical, genomic and molecular information from anonymous patients. The project brings together key stakeholders in the clinical, academic, patient, HTA (health technology assessment), regulatory, economical, ethical and pharmaceutical field.